Edition:
United States

Ionis Pharmaceuticals Inc (IONS.OQ)

IONS.OQ on NASDAQ Stock Exchange Global Select Market

53.57USD
13 Dec 2017
Change (% chg)

-- (--)
Prev Close
$53.57
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
412,644
52-wk High
$65.51
52-wk Low
$37.27

Select another date:

Mon, Dec 11 2017

UPDATE 1-'Ground-breaking' new drug gives hope in Huntington's disease

LONDON, Dec 11 Scientists have for the first time fixed a protein defect that causes Huntington's disease by injecting a drug from Ionis Pharmaceuticals into the spine, offering new hope for patients with the devastating genetic disease.

BRIEF-Ionis Pharma Says Roche Has Exercised Option To License IONIS-HTT(Rx)

* IONIS PHARMACEUTICALS LICENSES IONIS-HTT RX TO PARTNER FOLLOWING SUCCESSFUL PHASE 1/2A STUDY IN PATIENTS WITH HUNTINGTON'S DISEASE

BRIEF-Ionis eligible to get nearly $800 mln in milestones from deal with Janssen

* Ionis Pharmaceuticals licenses second orally delivered antisense drug to Janssen

BRIEF-Akcea and Ionis announce acceptance of marketing applications in U.S., EU and Canada for Volanesorsen

* Akcea and Ionis announce acceptance of marketing applications in U.S., EU and Canada for Volanesorsen for the treatment of FCS

BRIEF-Ionis Pharma, ‍Dynacure announces Dynacure has licensed IONIS-DNM2-2.5(Rx) (Dyn101)​

* Ionis Pharmaceuticals Inc - co, ‍Dynacure announced that Dynacure has licensed IONIS-DNM2-2.5(Rx) (Dyn101)​

BRIEF-Ionis Pharmaceuticals reports Q3 earnings per share $0.00

* Ionis Pharmaceuticals reports financial results and highlights for third quarter 2017

BRIEF-Ionis submits NDA for Inotersen to the U.S. FDA

* Ionis announces submission of new drug application (NDA) for Inotersen to the U.S. fda Source text for Eikon: Further company coverage:

BRIEF-Ionis submits marketing authorization application for Inotersen to the EMA

* Ionis announces submission of marketing authorization application for inotersen to the European Medicines Agency Source text for Eikon: Further company coverage:

BRIEF-Ionis Pharmaceuticals announces plans to open expanded access program to provide Inotersen to patients

* Ionis pharmaceuticals announces plans to open expanded access program to provide Inotersen to patients with hereditary TTR Amyloidosis in the U.S.

BRIEF-IONIS PHARMACEUTICALS TO COLLABORATE WITH SEVENTH SENSE BIOSYSTEMS

* IONIS ENTERS INTO COLLABORATION WITH SEVENTH SENSE BIOSYSTEMS TO SUPPORT DEVELOPMENT OF IMPROVED BLOOD COLLECTION AND DIAGNOSTIC DEVICE

Select another date: